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Abstract An important component of the extracellular matrix
is the group of non-collagenous proteins belonging to the small
leucine-rich repeat (SLR) protein family. A new SLR protein,
podocan, with structural characteristics di¡erent from the
known classes of the SLR protein family has been identi¢ed
recently from the kidney. In this study, we examined the func-
tional characteristics of this SLR protein expressed in cultured
cells. Podocan was clearly observed intracellularly and was also
detectable in the supernatant. Treatment of the expressed pro-
tein with various glycoenzymes suggested that podocan is a
glycoprotein containing N-linked oligosaccharides but not a
classical proteoglycan. Moreover, podocan was found to bind
type 1 collagen. Cells transfected with podocan showed reduc-
tions in cell growth and migration, concomitant with increased
p21 expression. Podocan mRNA was detected by reverse tran-
scription polymerase chain reaction not only in the kidney, but
also in other tissues including the heart and vascular smooth
muscle cells, suggesting that podocan may have a potential
role in growth regulation in cardiovascular tissues.
, 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The extracellular matrix is a complex mixture of macromo-
lecules including collagens, ¢bronectins, proteoglycans, and
other related molecules, which interact with each other and
other bioactive compounds, and comprise up to 30% of total
body proteins. One of the components of the extracellular
matrix is a group of non-collagenous glycoproteins known
collectively as the small leucine-rich repeat (SLR) protein fam-
ily [1]. A unique feature of the members of this family is the
fact that they share a common structural motif, the leucine-
rich repeat (LRR) domain, which is 20^29 amino acids long,
contains asparagine and leucine residues in conserved posi-
tions, and has a general consensus sequence LXXLXL-
XXNXL/I [2].
Previous studies have demonstrated that the SLR proteins
may play an important role in the pathophysiology of a vari-
ety of diseases including atherosclerosis and renal disease
[3,4]. For example two major SLR proteins, biglycan and
decorin, have been implicated in the control of cell growth,
collagen deposition, and the activation and inactivation of
cytokines and growth factors [1,2,5]. Expression of these
SLR proteins in the kidney and vasculature is controlled by
growth factors, cytokines, and vasoactive hormones, and is
a¡ected by drug treatment [6^8].
Recently, a novel member of the SLR protein family, po-
docan, which is expressed in the sclerotic glomerular lesion
of experimental human immunode¢ciency virus-associated
nephropathy (HIVAN) has been identi¢ed [9]. Previously,
the SLR protein family was divided into four classes based
on the number of LRRs, the composition of the N-terminal
cysteine cluster, and the number of exons. Podocan di¡ers
from the known SLR proteins in all three parameters, and
can therefore be considered the ¢rst member of a new (¢fth)
class of the SLR protein family.
At present the function of this novel SLR protein is unclear.
Recent studies have shown not only that the SLR proteins
may play a major role in the pathogenesis of vascular and
renal disease, but also that these molecules are potential can-
didates for the gene therapy of proliferative and ¢brotic dis-
eases [10,11]. The aim of this study was therefore to examine
if podocan has functional e¡ects on cell growth and migratory
properties when expressed in cultured cells, and to examine if
podocan is expressed in extra-renal tissues.
2. Materials and methods
2.1. Identi¢cation of the podocan gene and construction of recombinant
podocan-tag fusion protein
The human biglycan protein was used as a query sequence in the
screening of the human genome g scan protein database using the
BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) to identify
novel SLR proteins, and the best candidate sequence was found to
be identical to the sequence of podocan which has been recently iden-
ti¢ed by representational di¡erence analysis of cDNA in kidney po-
docytes from mice with and without HIVAN [9], and to an unidenti-
¢ed IMAGE consortium clone image 7489773R from a human brain
library in pCMVSPORT6 (American Type Culture Collection
(ATCC)). Human podocan cDNA was subcloned into the pcDNA3.1
V5/His-Topo vector (Invitrogen) after polymerase chain reaction
(PCR) ampli¢cation of the podocan full-length coding region with
the primers 5P-TTCCATCAGCCCT-3P and 5P-TCTTGTTTCCTC-
TTCCTCC-3P using exTaq polymerase (Takara). In-frame ligation
of the podocan cDNA into the pcDNA3.1 V5/His-Topo vector (In-
vitrogen) was performed according to the manufacturer’s instructions,
and the construct was sequenced using the ABI Prism Big Dye Kit
(Applied Biosystems) to ensure ¢delity.
2.2. Transfection of podocan into cultured cells
COS-7 cells and CHO-K1 cells were purchased from ATCC. For
transient transfection assays, COS-7 cells were transfected with
0014-5793 / 04 / $30.00 J 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0014-5793(04)00250-9
*Corresponding author. Fax: (81)-3-3359 2745.
E-mail address: sasamura@sc.itc.keio.ac.jp (H. Sasamura).
FEBS 28217 29-3-04 Cyaan Magenta Geel Zwart
FEBS 28217 FEBS Letters 563 (2004) 69^74
pcDNA3.1 V5/His-Topo vector containing podocan-V5 tag fusion
cDNA, or with empty vector using lipofectamine [12]. For stable
transfections, CHO-K1 cells were transfected either with pcDNA3.1
V5/His-Topo vector containing podocan-V5 tag fusion cDNA for
immunocytochemical studies and immunoblot analyses, or with
pCMVSPORT6 containing full-length native brain podocan cDNA
for analysis of the e¡ects of the protein on cell growth and migration.
Control cells were transfected with vector alone. Stable transfectant
were isolated by selection with geneticin (400 Wg/ml).
2.3. Immunocytochemistry
Transfected COS-7 and CHO-K1 cells were incubated on coverslips
in culture medium for 24 h. Cultures were ¢xed in ethanol at 320‡C,
washed, and blocked with 1% bovine serum albumin (BSA) in phos-
phate-bu¡ered saline (PBS) for 30 min. Cells were labeled with anti-
V5 antibody (Invitrogen) at a concentration of 1:200 for 1 h at room
temperature, washed, and then labeled with £uorescein isothiocya-
nate-conjugated anti-mouse goat IgG (Chemicon) diluted at 1:500.
After the ¢nal wash, the cultures were embedded in Vectashield (Vec-
tor) and visualized with confocal microscopy (Karl Zeiss).
2.4. Enzymatic deglycation
The transfected CHO-K1 cells in six-well plates were washed and
scraped into 200 Wl of 0.5% Nonidet P-40 in PBS. After homogeniza-
tion, the samples were cleared by centrifugation and subjected to
glycoenzymatic digestions. Samples were digested with 10 mU chon-
droitinase ABC (Seikagaku Kogyo) in 1Uchondroitinase ABC bu¡er
(33 mM Tris^HCl, 33 mM sodium acetate, 0.08 mg/ml BSA) or 10 mU
heparitinase I in 1Uheparitinase bu¡er (0.1 M sodium acetate, 10 mM
calcium acetate, pH 7.0) or 10 mU keratanase II in the same bu¡er at
37‡C overnight. For N-glycosidase F digestion, the samples were
boiled at 100‡C for 3 min in 0.1% sodium dodecyl sulfate (SDS),
0.1 M L-mercaptoethanol, cooled on ice, then 0.05 M EDTA was
added prior to digestion with 2 U N-glycosidase F (Ho¡man-La
Roche) overnight at 37‡C. Samples were run on 4^12% SDS^polyac-
rylamide gel electrophoresis (PAGE) gels and transferred to nitrocel-
lulose membrane (Amersham Bioscience), and subjected to Western
blotting using anti-V5 antibody (1:500, Invitrogen) using previously
described protocols [7].
2.5. SDS^PAGE of 35S-labeled proteins
Transfected COS-7 cells were grown in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) containing 5% fetal calf serum (FCS) for 24 h and
the medium was changed to sulfate-free medium supplemented with
[35S]sulfate (Amersham) (10 WCi/ml) for 48 h. The [35S]sulfate-labeled
medium was collected and digested with or without chondroitinase
ABC as described above, and the 35S-labeled proteoglycans were pre-
cipitated with 1.3% potassium acetate in ethanol. The precipitate was
resuspended in 1ULaemmli bu¡er and run on 8^12% SDS^PAGE
gels. The gels were ¢xed in 10% methanol, 20% glacial acetic acid,
70% water, vacuum-dried, then the labeled proteoglycans were visu-
alized using a BAS 2000 image analyzer (Fuji).
2.6. Collagen binding assay
Collagen binding assays were performed using a modi¢cation of a
method described by Svensson et al. [13]. CHO-K1 cells expressing
podocan-tag fusion protein in six-well plates were washed twice with
PBS and the cell layer was scraped in 200 Wl of 0.5% Nonidet P-40 in
1Uchondroitinase ABC bu¡er (33 mM Tris^HCl, 33 mM sodium
acetate, pH 8.0, 0.08 mg/ml BSA). The collected cell layer was ho-
mogenized and centrifuged, then 0.1 ml of the lysate was incubated
for 5 h at 37‡C with or without 15 Wl of acid-solubilized bovine type 1
collagen (1 mg/ml, Sigma). The incubated sample was centrifuged for
5 min at 10 000Ug. The supernatant was removed and the precipitate
was washed once with PBS. The precipitate, the supernatant, and a
control uncentrifuged sample were subjected to Western blotting as
described above using anti-V5 antibody as the primary antibody.
2.7. Assays of cell proliferation, thymidine incorporation, and cell
migration
Subcon£uent CHO-K1 cells transfected with native podocan cDNA
were made quiescent by changing to serum-free medium for 48 h then
stimulated with 2% FCS. To assess the cell numbers on days 0, 2, and
4 after the stimulation, cell proliferation was assessed using a water-
soluble tetrazolium cell counting kit (Promega). To assess changes in
[3H]thymidine incorporation, [3H]thymidine (New England Nuclear,
1 WCi/ml) was added 24 h after stimulation, then the cells were har-
vested for the quantitation of [3H]thymidine incorporation into tri-
chloroacetic acid-precipitable material after a further 24 h [5]. Cell
migration assays were performed using a modi¢ed Boyden’s chamber
method as described by Nozawa et al. [14] with minor modi¢cations.
In brief, cells were suspended in serum-free DMEM+0.1% BSA and
added to chambers containing a 8 Wm pore size polycarbonate ¢lter
(Chemotaxicel, Kurabo). 2% FCS was added to the lower chamber in
DMEM+0.1% BSA. The chambers were incubated at 37‡C for 12 h,
then the ¢lters were removed, ¢xed in methanol, and stained with
Mayer’s solution. Cells from four randomly chosen high-power ¢elds
on the lower surface of the ¢lter were counted.
2.8. Assays of p21 expression, cdk2 expression, and Rho A activity
For the assay of p21 expression, CHO-K1 cells transfected with
native podocan cDNA or vector were lysed in ice-cold RIPA bu¡er
(1UPBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
10 Wg/ml phenylmethylsulfonyl £uoride, 30 Wg/ml aprotinin, 1 mM
sodium orthovanadate). Lysates were normalized for protein content,
then subjected to Western blot analysis using anti-cdk2 and anti-p21
antibodies (Santa Cruz Biotechnology). Rho A activity was assessed
by GTP-Rho a⁄nity precipitation assays as described by Ren et al.
[15]. Serum-starved cells were lysed in 50 mM Tris^HCl bu¡er, pH
7.2, containing 500 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 10 Wg/ml leupeptin, 10 Wg/ml apro-
tinin, and 100 Wg/ml phenylmethylsulfonyl £uoride. To detect GTP-
associated active Rho A, lysates containing equal amounts of protein
were incubated with Rhotekin Rho binding domain agarose (Upstate
Biotechnology) at 4‡C for 45 min. The bound protein were eluted with
1ULaemmli sample bu¡er, and detected by immunoblotting using a
monoclonal antibody against Rho A (Upstate Biotechnology, Lake
Placid, NY, USA). Total Rho expression was assessed by immuno-
blotting of an 1/20 aliquot from the supernatant prior to a⁄nity
precipitation. The relative intensities of the bands were assessed using
computer densitometry software (Scion Image).
2.9. Reverse transcription (RT) PCR analysis of podocan mRNA
expression in human tissues and cultured vascular smooth muscle
cells (VSMC)
A commercial human multiple-tissue cDNA panel (Clontech) con-
taining cDNAs from eight human tissues was used to screen for po-
docan mRNA expression. VSMC were obtained from rat aorta, and
RNA puri¢ed by the acid guanidine^phenol^chloroform method as
described previously [6]. Ampli¢cation reactions were carried out us-
ing AmpliTaq polymerase (Perkin-Elmer) with 30 ampli¢cation cycles
of 95‡C for 1 min, 55‡C for 1 min and 72‡C for 2 min, and ¢nal
elongation at 72‡C for 10 min. The sense and antisense primers (5P-
ACCTGCAAAACAACCGCCTG-3P and 5P-TGTTCTTGAGGTG-
CAGCTTG-3P) for studies on the human tissues resulted in a 366-
bp product corresponding to bases 535^900 in the human sequence.
The primers for studies on VSMC (5P-TGTCCAGCAACAACCTGT-
3P and 5P-GGGCTGGTGATGCGGTTGTA-3P) were designed from
areas of high homology in the human and mouse sequences and
resulted in a 373-bp product corresponding to bases 1042^1414. In
some experiments, the reaction products were subcloned into
pcDNA3.1 V5/His-Topo vector (Invitrogen) and sequenced to con¢rm
identity with podocan. Commercial glyceraldehyde-3-phosphate dehy-
drogenase primers were obtained from Clontech.
2.10. Statistics
Statistical analyses were performed by analysis of variance using
Statview software. Results are presented as meanUS.E.M.
3. Results and discussion
3.1. Identi¢cation of the podocan gene in silico
We used the BLASTP algorithm to search for sequences
homologous to biglycan in the human genome g scan protein
database, and found a sequence identical to podocan, a SLR
protein independently identi¢ed from the kidneys of mice with
HIVAN [9].
As reported by Ross et al. [9], the four amino-terminal
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cysteines of podocan show a CX3CXCX7C pattern, which is
unlike any other characterized member of the SLR protein
family. The podocan gene was localized in silico to human
chromosome locus 1p23. Comparison of cDNA and genomic
sequences shows that the gene spans over 23.3 kb, and con-
sists of 13 exons. Since the composition of the amino-terminal
cysteines, the number of LRRs (20), and the number of exons
is di¡erent from known SLR proteins, podocan may be con-
sidered the ¢rst member of a new class in the SLR protein
family.
3.2. Visualization of podocan in transfected cells
To investigate the glycosylation and functional properties
of podocan, podocan cDNA was subcloned in-frame in a V5
tag-containing vector and expressed as a tag fusion protein in
COS-7 and CHO-K1 cells. Immunostaining with anti-V5 anti-
body showed that the podocan-tag fusion protein could be
clearly visualized in the cytoplasm but not on the cell mem-
brane (Fig. 1A), suggesting that it is not a membrane-bound
protein, a ¢nding which is compatible with the absence of
predicted transmembrane helices in the podocan protein mo-
tif. Moreover, the fusion protein was also detectable in the
culture supernatants by immunoblotting, compatible with se-
cretion of the protein into the supernatant (data not shown).
3.3. Glycoenzymatic characterization of podocan protein
The protein has four potential N-glycosylation site at Asn
214, 281, 299 and 410, de¢ned by the consensus sequence Asn-
Xaa-Ser/Thr. Treatment of podocan with N-glycosidase F
con¢rmed that podocan contains N-linked oligosaccharides
as shown by the change in its mobility on SDS^PAGE after
treatment with N-glycosidase F (Fig. 1B). On the other hand,
treatment of podocan with other glycoenzymes speci¢c for
glycosaminoglycan (GAG) side chains showed no mobility
shift on SDS^PAGE. Moreover, COS-7 cells transfected
with podocan fusion protein showed no detectable increase
in 35S-labeled proteins compared to vector-transfected cells,
in contrast to cells transfected with the positive control SLR
protein biglycan (Fig. 1C). Of interest, the observed molecular
weight of podocan after N-glycosidase F digestion was similar
to the expected molecular weight (V70 kDa) for unmodi¢ed
protein based on the amino acid sequence. All these results
suggest that podocan is an N-linked glycoprotein which is not
expressed as a proteoglycan in these cells.
Although the majority of SLR proteins are covalently
bound to GAG chains, there are exceptions such as asporin,
another member of the class I extracellular matrix SLR pro-
teins, which does not exist as a proteoglycan [16]. Although
the podocan sequence contains one consensus GAG attach-
ment motif (Ser-Gly) in its amino-terminus, it lacks the car-
boxy-terminal cysteine residues involved in disul¢de forma-
tion. Some extracellular matrix SLR proteins with GAG
side chains are known to exist in both non-sulfated and sul-
fated forms (‘part-time proteoglycans’). For example, arterial
lumican, one of the extracellular matrix SLR proteins and
keratan sulfate proteoglycan, has no sulfated side chains,
while corneal lumican exists in highly sulfated proteoglycan
form [17,18]. Therefore, the possibility that podocan may exist
as a proteoglycan in other cells and tissues cannot be ruled
out.
3.4. Interaction of podocan with collagen
Recombinant podocan-tag fusion protein produced by
transfected CHO-K1 cells was analyzed for its binding to
type 1 collagen. When cell lysates were incubated without
collagen then centrifuged, recombinant podocan protein was
Fig. 1. A: Immunocytochemical visualization of recombinant podocan fusion protein in COS-7 and CHO-K1 cells. Cells were transfected with
pCDNA3.1 V5/His-Topo podocan plasmid and immunostained by anti-V5 antibody as described in Section 2. B: Glycoenzymatic digestion of
recombinant podocan-tag fusion protein. Recombinant podocan-tag fusion protein expressed in CHO-K1 cells was digested with or without the
enzymes chondroitinase ABC (chABC), heparitinase, keratanase or N-glycosidase F. Digested products were subjected to Western blotting using
anti-V5 antibody. C: SDS^PAGE of 35S-labeled podocan-transfected COS-7 cells. COS-7 cells were transiently transfected with
pCMVSPORT6-podocan or pcDNA 3.1-biglycan (positive control) or vector alone. The transfected cells were labeled with [35S]sulfate and sam-
ples from the medium and the cell layer were subjected to SDS^PAGE. D: Collagen binding assays of podocan. Recombinant podocan-tag fu-
sion protein was incubated with or without collagen type 1, centrifuged, and subjected to Western blotting as described in Section 2. T: total
podocan, S: podocan in supernatant, P: podocan in precipitate.
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totally recovered in the supernatant. When the expressed po-
docan was coincubated with type 1 collagen, podocan re-
combinant protein coprecipitated with the collagen ¢brils
and none of the protein was detected in the supernatant, sug-
gesting that podocan was bound to this collagen (Fig. 1D).
Collagen binding is a common feature of SLR proteins, but
the nature of the binding appears to depend on the sequence
of each SLR protein, since decorin, one of the class I SLR
proteins, binds to collagen via its LRR 4^5 on the core pro-
tein, whereas the related SLR protein biglycan does not
[13,19].
3.5. E¡ects of podocan on cell growth and cell cycle protein
expression
Several studies have shown that many SLR proteins have
cell growth-regulatory properties [1,2]. Biglycan has an inhib-
itory e¡ect on the proliferation of ¢broblasts [5], while decorin
inhibits cell growth through interactions with cell cycle pro-
teins [20]. We hypothesized that podocan might also have an
e¡ect on cell proliferation because of its structural similarity
to these SLR proteins. Comparison of cell proliferation and
[3H]thymidine incorporation showed suppression of cell
growth and DNA synthesis in podocan-expressing CHO-K1
cells when compared with vector-transfected CHO-K1 cells
(Fig. 2A,B). To examine if these changes were associated
with changes in the expression of cell cycle proteins, we
studied the expression level of the cell cycle regulatory pro-
teins, p21 and cdk2 (Fig. 2C). Podocan overexpression was
associated with an increase in p21 expression, whereas cdk2
expression in the same cells was attenuated. Activation of a
cdk2^cyclin complex during the G1 phase is involved in the
G1 to S phase transition and this complex is inhibited by the
cdk inhibitor p21 [21]. Therefore our ¢ndings concerning p21
and cdk2 levels are consistent with the anti-proliferative ef-
fects of podocan which we found in this study. On the other
hand, in order to assess the biological signi¢cance of the ob-
Fig. 3. E¡ects of podocan on cell migration. CHO-K1 cells were stably transfected with pCMVSPORT6-podocan or vector. A: Comparison of
cell migration. B: Comparison of Rho activity. Upper panel: Representative Western blot. Lower panel: Results of densitometry. Experiments
were performed on cells from two independent transfections with similar results. *P6 0.05 podocan vs. vector (n=4).
Fig. 2. E¡ects of podocan on cell proliferation. CHO-K1 cells were stably transfected with pCMVSPORT6-podocan or vector. A: Comparison
of cell proliferation. B: Comparison of [3H]thymidine incorporation. C: Comparison of p21 and cdk2 expression. Upper panel: Representative
Western blot. Lower panel: Results of densitometry. Experiments were performed on cells from two independent transfections with similar re-
sults. *P6 0.05, **P6 0.01 podocan vs. vector (n=4).
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served changes, further studies using exogenous podocan in a
variety of cell lines are required, since the possibility that
podocan has di¡erent e¡ects in di¡erent cell types, or that
exogenous podocan may have a di¡erent e¡ect than endoge-
nously overexpressed podocan cannot be completely ruled
out.
3.6. E¡ects of podocan on cell migration and Rho A activity
Cell migration is crucial for many vascular pathological and
physiological processes, such as the repair of injured blood
vessels, angiogenesis, and atherogenesis. Cell movement is
controlled by a variety of growth factors and extracellular
matrix proteins and accompanied by the formation of stress
¢bers in vivo. Recently, Tufvesson showed that the small pro-
teoglycans biglycan and decorin increase cell migration with
cytoskeletal changes and the activation of Rho A in lung
¢broblasts [22]. We therefore investigated whether the novel
glycoprotein podocan a¡ects cell migration and Rho activity
using CHO cells stably expressing human podocan or vector.
Overexpression of podocan in CHO cells resulted in signi¢-
cant suppression of cell migration compared to the cells trans-
fected with the vector (Fig. 3A). Moreover, podocan-trans-
fected cells showed a modest decrease in Rho A activity
compared to vector-transfected cells (Fig. 3B).
3.7. Tissue distribution of podocan
RT-PCR analysis of a commercial cDNA panel was per-
formed to screen for the tissue distribution of podocan in
multiple human tissues. A weak but consistently detectable
signal was found in the kidney. Of interest, more robust sig-
nals for podocan mRNA were also found in the heart as well
as the liver and pancreas (Fig. 4A). RT-PCR analysis was also
performed on cultured VSMC. Podocan mRNA was readily
detectable in VSMC. Moreover, the expression of podocan
mRNA appeared enhanced in cells treated for 24 h with an-
giotensin II (Ang II) (Fig. 4B), consistent with our previous
report that Ang II is a major regulator of SLR protein ex-
pression in the vasculature [6].
3.8. Conclusion
The structural features of podocan have suggested that it is
a member of a novel class of the SLR protein family. The
results of this study suggest that it can be expressed in a non-
proteoglycan form, associates with type 1 collagen, and exerts
anti-proliferative and anti-migratory e¡ects concomitant with
changes in p21 and Rho activity. The ¢nding of podocan
mRNA expression in the heart and VSMC may be of impor-
tance, since members of the SLR protein family may play a
major role in the pathogenesis of cardiovascular disease and
atherosclerosis. Finally, other SLR proteins such as decorin
are prospective candidates for the gene therapy of ¢brotic and
proliferative diseases. In view of the potential anti-prolifera-
tive e¡ects of podocan, further studies are warranted to ex-
amine if podocan could be a useful addition to our armamen-
tarium for the therapy of ¢brotic or proliferative diseases.
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